One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Atossa Therapeutics, Inc.
ATOS · NCM · Healthcare · Biotechnology
Current price
$2.39
52-week range
$1.70 - $16.50
Market cap
$23.84M
Balance sheet
Healthy
-15.63x Concerning
Net cash $26.09M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -89.2% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 1.8% (peer median: 1.9%).
What this company does
Atossa Therapeutics, Inc.
Atossa Therapeutics is a company trying to create new medicines for cancer. Their main focus is on a pill called (Z)-endoxifen, which is being tested to treat and help prevent breast cancer. The money they have comes from selling stock and funding from investors, as they are still developing their products and don't have any drugs on the market yet.
How the company got here
Atossa Therapeutics, Inc. was founded in 2008 and was formerly known as Atossa Genetics Inc.. The company rebranded to Atossa Therapeutics, Inc. in January 2020, signaling a strategic shift towards developing medicines for oncology. This evolution reflects a focus on addressing significant unmet medical needs within cancer treatment. The company's journey is marked by its transition from its earlier identity to its current focus on clinical-stage biopharmaceutical development.
What it actually does
Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer and other serious diseases with unmet medical needs. Their primary work involves creating new drug therapies, with a lead candidate called (Z)-endoxifen. This drug is currently in clinical development, meaning it's being tested in human trials to see if it's safe and effective. The company's efforts are centered on advancing these potential treatments through the rigorous process of drug development, aiming to bring new options to patients.
Z-endoxifen for Breast Cancer
Atossa's main focus is the development of (Z)-endoxifen, a drug candidate primarily aimed at treating and reducing the risk of breast cancer. (Z)-endoxifen is a type of medication known as a selective estrogen receptor modulator and degrader (SERM/D). It works by targeting estrogen receptors, which play a role in the growth of certain breast cancers. The company is investigating (Z)-endoxifen across various stages of breast cancer, including metastatic breast cancer (cancer that has spread to other parts of the body), and for risk reduction. They are also exploring its use in combination with other cancer therapies. Atossa is developing a special oral formulation of (Z)-endoxifen designed to improve how the drug is absorbed and used by the body.
Z-endoxifen for Rare Diseases
Beyond breast cancer, Atossa Therapeutics is also exploring the potential of (Z)-endoxifen to treat rare diseases. One such area is Duchenne Muscular Dystrophy (DMD), a serious and progressive genetic disorder that primarily affects young boys. The U.S. Food and Drug Administration (FDA) has granted 'Rare Pediatric Disease' designation for (Z)-endoxifen in the treatment of DMD, which is a significant regulatory step. This designation acknowledges the potential of (Z)-endoxifen to address a critical unmet need in this patient population. The company views (Z)-endoxifen as a versatile molecule with the potential to help in multiple disease areas.
What management is betting on now
Atossa's management is strategically focused on advancing (Z)-endoxifen through clinical trials to gain regulatory approval for breast cancer treatments. A key priority is to accelerate the development of (Z)-endoxifen, particularly for metastatic breast cancer, where there is a significant need for new therapies. The company is also actively engaging with regulatory bodies like the FDA to streamline the development process. In parallel, they are pursuing the potential of (Z)-endoxifen in rare diseases, such as Duchenne Muscular Dystrophy, viewing it as a platform molecule with broader therapeutic possibilities. This dual approach aims to maximize the value and impact of their lead drug candidate.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-4.76M
FY2024 Q4
$-7.05M
FY2025 Q1
$-5.97M
FY2025 Q2
$-7.26M
FY2025 Q3
$-6.01M
FY2025 Q4
$-10.55M
FY2026 Q1
$-9.58M
FY2026 Q2
$-9.64M
Revenue
—
Net income
$-8.49M
Diluted EPS
-0.95
Operating cash flow
$-9.64M
Free cash flow
$-9.64M
Fetching…
Sources
Revenue
—
Net income
$-9.59M
Diluted EPS
-1.11
Operating cash flow
$-9.58M
Free cash flow
$-9.58M
Fetching…
Sources
Revenue
—
Net income
$-10.94M
Diluted EPS
-3.85
Operating cash flow
$-10.54M
Free cash flow
$-10.55M
Fetching…
Sources
Revenue
—
Net income
$-8.69M
Diluted EPS
-0.07
Operating cash flow
$-6.00M
Free cash flow
$-6.01M
Fetching…
Sources
Revenue
—
Net income
$-8.42M
Diluted EPS
-0.07
Operating cash flow
$-7.26M
Free cash flow
$-7.26M
Fetching…
Sources
Revenue
—
Net income
$-6.72M
Diluted EPS
-0.05
Operating cash flow
$-5.96M
Free cash flow
$-5.97M
Fetching…
Sources
Revenue
—
Net income
$-6.35M
Diluted EPS
-0.04
Operating cash flow
$-7.05M
Free cash flow
$-7.05M
Fetching…
Sources
Revenue
—
Net income
$-7.23M
Diluted EPS
-0.06
Operating cash flow
$-4.75M
Free cash flow
$-4.76M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $2.39
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $26.1M - more cash than debt. Interest coverage -15.6x.
Net debt
$-26.09M
Interest coverage
-15.63x
Atossa Therapeutics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
ATOS
BASELINE
Atossa Therapeutics, Inc.
Total debt $0.00 Interest coverage -15.63x This is the baseline the peer rows are being compared against.
Total debt $677.00K Interest coverage -12.21x Neither company has much profit cushion over interest right now.
Total debt $135.62M Interest coverage -50.24x Neither company has much profit cushion over interest right now.
Total debt $1.19B Interest coverage -48.80x Neither company has much profit cushion over interest right now.
Total debt $739.72M Interest coverage -12.82x Neither company has much profit cushion over interest right now.
Total debt $165.93M Interest coverage 12.90x This peer still has a real interest-payment cushion, while ATOS does not.
What you should know
The case for and against ATOS
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -89.2% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 1.8% (peer median: 1.9%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.72x
P/B
0.89x
P/S
—
EV/EBITDA
0.06x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-89.2%
ROA
-50.7%
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
5.69x
Quick ratio
4.79x
Total debt
$0.00
Total cash
$26.09M
Growth
How the business has been compounding
Revenue TTM
$-5.34M
Revenue 5Y CAGR
-75.4%
EPS TTM
-4.45
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-35.77M
Free CF TTM
$-29.79M
FCF margin
558.0%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—